Zymeworks Inc. (ZYME)
After hours:
| Previous close | 9.25 |
| Open | 9.23 |
| Bid | 9.42 x 1000 |
| Ask | 9.87 x 1000 |
| Day's range | 9.18 - 9.93 |
| 52-week range | 4.11 - 10.80 |
| Volume | |
| Avg. volume | 1,187,375 |
| Market cap | 597.205M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.97 |
| Earnings date | 22 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.45 |
- Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, January 25, 2023--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
- PR Newswire
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced tolerability and efficacy results, including the first overall survival (OS) data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
- Business Wire
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
VANCOUVER, British Columbia, January 04, 2023--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year.
